Clinical trial
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With…
NCT00202917 · University Hospital Tuebingen, Other · Completed
Key facts
| NCT number | NCT00202917 |
|---|---|
| Title | Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies |
| Official title | Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies |
| Lead sponsor | University Hospital Tuebingen, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies |
| Intervention type | Drug, Procedure |
| Interventions | Fludarabine, Thiotepa, Melphalan, OKT-3, CD3/CD19 depletion on CliniMACS |
| Enrollment | 61 |
| Start date | Feb 1, 2004 |
| Primary completion | Jul 1, 2009 |
| Completion | Dec 1, 2010 |
| First posted | Sep 20, 2005 |
| Last update posted | May 29, 2014 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: